tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Soleno Therapeutics Corrects Q4 Financial Reporting Error

Soleno Therapeutics Corrects Q4 Financial Reporting Error

Meet Your ETF AI Analyst

Soleno Therapeutics Inc (SLNO) has issued an update.

A revised press release by Soleno Therapeutics, Inc. has corrected a minor reporting error in their financial results for Q4 and the full year of 2023. The adjusted figure for general and administrative expenses is now accurately stated as $4,140 for the quarter ending December 31, 2023, rectifying the previous misstatement of $4,410. This update ensures investors have precise information for their financial assessments.

See more insights into SLNO stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1